Skip to main content
Fig. 7 | Alzheimer's Research & Therapy

Fig. 7

From: Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease

Fig. 7

Predicted impact of patient baseline characteristics on PK profile of crenezumab and plasma Aβ levels. White vertical line refers to the predicted parameters for a 72-year-old male, weighing 72.3 kg, with a GFR of 72.5 mL/min/1.73 m2 after a crenezumab 60 mg/kg IV dose. Red bar depicts the 5th–95th percentile crenezumab exposure (left column) or Aβ levels (right column) range across the entire population. Green bar represents the influence of a single covariate on the predicted parameters. The upper and lower values for each covariate represent 90% of the observed covariate range in the population. Abbreviations: Aβ beta-amyloid, AUC area under the curve, BWT body weight, Cmax peak concentration, GFR glomerular filtration rate, IV intravenous, PK pharmacokinetics

Back to article page